Radioimmunotherapy in patients with head and neck squamous cell carcinoma: Initial experience

Head and Neck

Volumn 23, Issue 7, 2001, Pages 559-565

  Colnot, David R ^a   Quak, Jasper J ^a   Roos, Jan C ^a   de Bree, Remco ^a   Wilhelm, Abraham J ^a   Snow, Gordon B ^a   van Dongen, Guus A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Head and neck cancer; Monoclonal antibodies; Radioimmunotherapy

Indexed keywords

CHIMERIC ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY U36; MONOCLONAL ANTIBODY U36 RE 186; RHENIUM 186; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TUMOR LOCALIZATION; WHOLE BODY SCINTISCANNING;

AGED; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOTHERAPY DOSAGE; RECOMBINANT FUSION PROTEINS; RHENIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0034978363     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.1078     Document Type: Article

References (20)

1. Head and neck cancer
2. Adjuvant therapy in head and neck cancer
3. Continuous cultures of fused cells secreting antibody of predefined specificity
4. Iodine-131-Anti-B1 radioimmunotherapy for B-cell lymphoma
5. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody
6. Radioimmunotherapy of patients with small-volume tumors using iodine-131-1abeled anti-CEA monoclonal antibody NP-4 F(ab′)2
7. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG
8. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck
9. Radioimmunoscintigraphy and biodistribution of 99mTc-labeled monoclonal antibody U36 in patients with head and neck cancer
10. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies
11. Rhenium-186-labeled chimeric antibody NR-LU-13: Pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10
12. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: Toxicity and clinical response
13. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: Results of phase I trials
14. Phase I therapy study of Rhenium-186-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck
15. Prediction of hematologic toxicity after radioimmunotherapy with 131I-labeled anticarcinoembryonic antigen monoclonal antibodies
16. Radiolabeled antibody combined with external radiotherapy for the treatment of head and neck cancer: Reconstruction of a theoretical phantom of the larynx for radiation dose calculation to local tissues
17. Safety and biodistribution of 99m Technetium-labeled anti-CD44v6 monoclonal antibody BIWA1 in head and neck cancer patients
18. Biodistribution of Indium-111-labeled OC125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian cancers
19. The impact of tumour volume and other characteristics on uptake of radiolabelled monoclonal antibodies in tumour tissue of head and neck cancer patients
20. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer